Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE) in Cystic Fibrosis Patients With Chronic Infections Due to Pseudomonas Aeruginosa

Trial Profile

Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE) in Cystic Fibrosis Patients With Chronic Infections Due to Pseudomonas Aeruginosa

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amikacin (Primary)
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Adverse reactions
  • Sponsors Transave
  • Most Recent Events

    • 18 Jun 2010 Status changed from recruiting to completed.
    • 18 Jun 2010 Results of the open-label extension of this trial have been presented at the 33rd European Cystic Fibrosis Society (ECFS), according to a Transave media release.
    • 13 Jun 2008 Added Transave as a sponsor, from Transave media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top